Welcome to our dedicated page for Stevanato Group S P A news (Ticker: STVN), a resource for investors and traders seeking the latest updates and insights on Stevanato Group S P A stock.
Stevanato Group S.p.A. (NYSE: STVN) is a global provider of drug containment, drug delivery, and diagnostic solutions for pharmaceutical, biotechnology, and life sciences companies. Its news flow, as reflected in recent press releases and SEC filings, centers on financial performance, capacity expansion, financing arrangements, and participation in healthcare investor conferences.
Investors following STVN news will find regular quarterly earnings announcements detailing revenue trends, segment performance for the Biopharmaceutical and Diagnostic Solutions and Engineering segments, margin evolution, and the growing contribution of high-value solutions such as high-performance Nexa® syringes and EZ-fill® vials and cartridges. These updates often include discussion of non-GAAP measures, capital expenditures, and liquidity.
News coverage also highlights strategic investments and footprint optimization, including expansions at manufacturing facilities in Cisterna di Latina and Fishers to increase pre-filled syringe and ready-to-use cartridge capacity, and enhancements at the Bad Oeynhausen, Germany, site for drug delivery system production. Financing news, such as the €200 million agreements with BNL BNP Paribas, Cassa Depositi e Prestiti, and Banco BPM, provides additional context on how Stevanato Group funds these projects.
In addition, Stevanato Group frequently announces its participation in major healthcare and investor conferences in locations such as New York, London, Las Vegas, Chicago, and Vienna. These events offer further insight into management’s views on market dynamics, high-value solutions, and long-term strategy.
By monitoring this page, readers can track Stevanato Group’s latest earnings releases, operational updates on capacity expansion and optimization plans, financing developments, and investor relations activities, all drawn from company-issued news and regulatory communications.
Stevanato Group S.p.A. (NYSE: STVN) announced it will release its third quarter fiscal 2021 financial results on November 9, 2021, at 6:30 a.m. ET. A conference call will follow at 8:30 a.m. ET, where management will present a slide deck available on their Investor Relations website. The call can be accessed by dialing provided numbers for various countries or via an online broadcast. A replay will be available until November 23, 2021. Founded in 1949, Stevanato is a key provider of drug containment, delivery, and diagnostic solutions for the pharmaceutical industry.
Summary not available.
Stevanato Group (NYSE:STVN) is set to commence construction of a new plant in Fishers, Indiana this month, with plans for completion by 2023. The facility, covering up to 370,000 square feet, represents an investment of approximately $145 million and aims to enhance support for North American pharmaceutical customers. It will produce the company's EZ-Fill® solutions and offer technical after-sales support. Stevanato Group anticipates hiring over 230 new employees by 2025 as part of its expansion strategy.
Stevanato Group (NYSE: STVN) reported second quarter 2021 revenue of €204.0 million, a 26% increase year-on-year, with gross margins rising to 31.2%. Net profit was €34.5 million, equating to €0.14 diluted EPS, including a €4.4 million one-time benefit. Adjusted diluted EPS was €0.12. The company forecasts 2021 revenue between €820 million and €830 million, with adjusted EPS expected to be between €0.43 and €0.47. Strong demand in its biopharmaceutical segment, driven by high-value solutions, contributed to growth. The company raised approximately $453.5 million in its IPO.
Summary not available.
Stevanato Group has priced its initial public offering of 32 million ordinary shares at $21 each, set to trade on the NYSE under the ticker symbol STVN starting July 16, 2021. The offering is anticipated to close on July 20, 2021, subject to standard conditions. Additionally, underwriters have a 30-day option to purchase 4.8 million more shares. The company has also entered into hedging agreements for $420 million and $180 million with Morgan Stanley to address currency exposure from the proceeds.